Metabolic Health Program Combining GLP-1 Medication with Behavior Change Publishes Annual Results Demonstrating 15% Average Weight Loss at 12, 18, & 24 Months and Reversal of Diabetes or Prediabetes Diagnosis in 81% of Participants

Calibrate’s second annual Results Report represents one of the largest real-world datasets on GLP-1 receptor agonist medications coupled with intensive lifestyle intervention

Calibrate is the first and only commercial platform to release outcomes analysis for the entirety of its population

NEW YORK--()--Calibrate, the leading metabolic health company, released its second annual Results Report, demonstrating continued effectiveness of the Company’s comprehensive care model to treat overweight and obesity, including a 15% average sustained weight loss at 12, 18, and 24 months. The clinically-reviewed data demonstrates overall metabolic health improvements, and notably, the reversal of diabetes and prediabetes diagnoses in 81% of members.

Calibrate’s 2023 Results Report tracked the outcomes of 2,643 members, representing all members who had completed Calibrate’s Metabolic Reset––a year-long, comprehensive program––and had at least one month of access to GLP-1 medication combined with intensive lifestyle intervention. The report includes the collective results of all members at 12 months in the Calibrate program (n=2,643), as well as for smaller subsets of all members who had continued to 18 (n=569) and 24 months (n=38) in Calibrate’s follow-on Masters Programs.

“We made a commitment to continuously publish our collective real-world results and today, we’re raising the bar for outcomes accountability with the wide-ranging impacts to metabolic health that we measured in this year’s report,” said Isabelle Kenyon, Calibrate’s Founder & CEO. “Our most recent Results Report validates our initial vision: that a comprehensive program combining medication with behavior change is the standard of care for obesity treatment. Our latest results are an important step in proving that effective obesity treatment can be delivered sustainably.”

Notably, Calibrate’s results represent real-world outcomes for its collective member population, which means that members who experienced interruptions in medication access such as inventory shortages, insurance coverage, or clinical contraindications, are included in the analysis. Analyzed members were initially treated with one of several GLP-1 medications––semaglutide, liraglutide, or dulaglutide––as determined clinically appropriate by their Calibrate doctor, covered by their commercial insurance plan, and in stock.

On average, Calibrate’s member outcomes across GLP-1 medications rival the clinical trial results (average 14.9% body weight loss at 68 weeks) of Wegovy®, one of the most effective GLP-1 medications to come to market.

“Calibrate’s real-world results demonstrate best-in-class outcomes and sustainability,” said Donna Ryan, MD, Calibrate Clinical Advisor and Past President of the World Obesity Federation, Professor Emerita, Pennington Biomedical Research Center, and Associate Editor of Obesity. “This is remarkable because it shows more sustained weight loss than the STEP 5 trials using Wegovy––while using a variety of different GLP-1 medications. This is important: Not all patients can access Wegovy. By combining medication with ILI in a purpose-built program, Calibrate is setting a new standard of care in obesity medicine.”

Calibrate combines GLP-1 medication with behavior change delivered through a proprietary intensive lifestyle intervention to treat the underlying biology that contributes to obesity. Dr. Ryan continues: “Calibrate has used rigorous methods to report weight loss and metabolic health data for the entire member population who have completed their program.” Calibrate’s results validate that a comprehensive program combining GLP-1 medication with purpose-built intensive lifestyle intervention is delivering a new standard of care for obesity treatment and improved metabolic health.

Outcomes of the n=2,643 members tracked and published in the report include:

  • On average, Calibrate members experienced 15.6% weight loss at 12 months (n=2,397), 15.9% at 15 months (n=1,319), 15.8% at 18 months (n=569), and 16.8% at 24 months (n=38).
    • 80% of Calibrate members lost enough weight in 12 months to move to a lower BMI category.
    • Further analysis was completed after publication for additional members tracked to 24 months (n=94) which demonstrated higher sustained weight loss averaging 17.8%.
  • On average, members (n=1,507) experienced a 5.95 inch reduction in waist circumference with 32% of members improving from “at risk,” meeting waist circumference criteria for metabolic syndrome, to “normal.”
  • 81% of members with diabetes or prediabetes showed a categorical improvement in their condition.

Calibrate’s second annual Results Report marks two years worth of clinically-validated results demonstrating that Calibrate is effective, and allows Calibrate to commit that every member will achieve at least 10% weight loss (terms and conditions apply). Calibrate is the only program to promise results that are also backed by published data, and to position both its direct-to-consumer and Enterprise business models on patient outcomes.

To read the full 2023 report, click here.

About Calibrate
Calibrate is on a mission to change the way the world treats weight. As the first outcomes-based model in obesity treatment, Calibrate is setting the standard of care with a digital program that combines medication with behavior change to improve overall metabolic health, allowing people to sustain long-term weight loss results after medication. Calibrate is the only program to guarantee results backed by clinically-reviewed data over a multi-year period.

Recognized as a World Economic Forum Technology Pioneer and by Fast Company’s World Changing Ideas, TIME’s Best Inventions, the Employer Health Innovation Roundtable Traction Awards, and Goldman Sachs Builders & Innovators, Calibrate has raised more than $125M in cumulative funding from leading healthcare and consumer investors, including Founders Fund, Tiger Global, Threshold Ventures, Forerunner Ventures, Optum Ventures, and Redesign Health.